

# Jae Seung Lee

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3530835/publications.pdf>

Version: 2024-02-01

55  
papers

518  
citations

858243

12  
h-index

939365

18  
g-index

57  
all docs

57  
docs citations

57  
times ranked

614  
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictive Performance of CAGE-B and SAGE-B Models in Asian Treatment-Naive Patients Who Started Entecavir for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e794-e807.	2.4	12
2	Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2022, 16, 290-299.	1.4	37
3	Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <math>\leq 2,000</math> IU/mL. <i>American Journal of Gastroenterology</i> , 2022, 117, 288-294.	0.2	8
4	Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients. <i>Cancers</i> , 2022, 14, 385.	1.7	6
5	External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study. <i>Cancers</i> , 2022, 14, 711.	1.7	1
6	Long-term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 289-296.	1.0	7
7	Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Gut and Liver</i> , 2022, 16, 786-797.	1.4	14
8	Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization. <i>Cancers</i> , 2022, 14, 67.	1.7	4
9	Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria. <i>Frontiers in Medicine</i> , 2022, 9, 869190.	1.2	8
10	Empirical Treatment With Carbapenem vs Third-generation Cephalosporin for Treatment of Spontaneous Bacterial Peritonitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 976-986.e5.	2.4	13
11	Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107747.	1.2	9
12	Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir. <i>Journal of Viral Hepatitis</i> , 2021, 28, 95-104.	1.0	8
13	Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Hepatology Research</i> , 2021, 51, 406-416.	1.8	5
14	Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2021, 62, 12.	0.9	6
15	Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma. <i>Cancer Investigation</i> , 2021, 39, 274-283.	0.6	1
16	Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization. <i>Current Oncology</i> , 2021, 28, 965-977.	0.9	2
17	A Case of Lymphocyte-Rich Hepatocellular Carcinoma in a Patient Who Was Treated for Colon Cancer. <i>Journal of Liver Cancer</i> , 2021, 21, 69-75.	0.3	2
18	External validation of CAGE and SAGE scores for Asian chronic hepatitis B patients with well-controlled viremia by antivirals. <i>Journal of Viral Hepatitis</i> , 2021, 28, 951-958.	1.0	6

#	ARTICLE	IF	CITATIONS
19	Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 295-304.	4.5	19
20	Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3123-3133.	1.2	3
21	Screening, confirmation, and treatment rates of hepatitis C virus infection in a tertiary academic medical center in South Korea. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2479-2485.	1.4	5
22	The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 467-476.	1.8	2
23	Risk assessment of hepatocellular carcinoma and liver-related events using ultrasonography and transient elastography in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1362-1372.	1.0	4
24	Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1168-1178.	2.9	28
25	No influence of hepatic steatosis on the 3-year outcomes of patients with quiescent chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1545-1553.	1.0	8
26	Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B. <i>Hepatology International</i> , 2021, 15, 1083-1092.	1.9	18
27	Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. <i>Cancers</i> , 2021, 13, 4567.	1.7	8
28	Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1570-1578.	1.0	15
29	Prevalence and Risk Factors of Cardiovascular Disease in Patients with Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	1.1	4
30	Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1703-1713.	1.4	12
31	Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 125-135.	4.5	3
32	Hepatitis B Virus Cure: Targets and Future Therapies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 213.	1.8	47
33	Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy. <i>Cancers</i> , 2021, 13, 5892.	1.7	6
34	An observational study on long-term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate. <i>Journal of Viral Hepatitis</i> , 2020, 27, 316-322.	1.0	13
35	Establishment and validation of a risk prediction model in patients with hepatocellular carcinoma treated with transarterial radioembolization. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 739-747.	0.8	2
36	Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals. <i>Cancers</i> , 2020, 12, 3414.	1.7	9

#	ARTICLE	IF	CITATIONS
37	Entecavir and tenofovir on renal function in patients with hepatitis B virus-related hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2020, 27, 932-940.	1.0	6
38	A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 24-32.	4.5	31
39	The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization. <i>Gut and Liver</i> , 2020, 14, 765-774.	1.4	20
40	Establishment of pancreatic cancer cell lines with endoscopic ultrasound-guided biopsy via conditionally reprogrammed cell culture. <i>Cancer Medicine</i> , 2019, 8, 3339-3348.	1.3	10
41	Conditional Survival Estimates Improve Over Time for Patients with Hepatocellular Carcinoma: An Analysis for Nationwide Korea Cancer Registry Database. <i>Cancer Research and Treatment</i> , 2019, 51, 1347-1356.	1.3	8
42	The significance of tubulointerstitial lesions in childhood Henoch-Schönlein nephritis. <i>Pediatric Nephrology</i> , 2016, 31, 2087-2093.	0.9	11
43	Noninfectious Complications of Peritoneal Dialysis in Korean Children: A 26-Year Single-Center Study. <i>Yonsei Medical Journal</i> , 2015, 56, 1359.	0.9	13
44	Outcomes of Hemodialysis in Children: A 35-Year Experience at Severance Hospital. <i>Yonsei Medical Journal</i> , 2015, 56, 1007.	0.9	4
45	Prevalence of Vesicoureteral Reflux According to the Timing of Voiding Cystourethrography in Infantile Urinary Tract Infection. <i>Journal of the Korean Society of Pediatric Nephrology</i> , 2011, 15, 163.	0.1	0
46	Relationship of Glomerular Basement Membrane Alterations to Epithelial Cell Structure and Clinical Parameters in Alport Syndrome. <i>Journal of the Korean Society of Pediatric Nephrology</i> , 2010, 14, 22.	0.1	0
47	Seven-Year Follow Up of Microscopic Polyangiitis Presenting with Rapidly Progressive Glomerulonephritis. <i>Journal of the Korean Society of Pediatric Nephrology</i> , 2008, 12, 99.	0.1	1
48	Analysis of renal biopsies performed in children with abnormal findings in urinary mass screening. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2006, 95, 849-853.	0.7	2
49	Diagnosis and Treatment of the Urinary Tract Infection in Febrile Infants and Children. <i>Korean Journal of Pediatric Infectious Diseases</i> , 2002, 9, 46.	0.1	0
50	A case of living-related kidney transplantation in Bartter's syndrome. <i>Yonsei Medical Journal</i> , 2000, 41, 662.	0.9	18
51	An analysis of 2361 cases of renal biopsy in Korea. <i>Yonsei Medical Journal</i> , 1991, 32, 9.	0.9	12
52	Significance of mesangial IgA deposition in minimal change nephrotic syndrome: a study of 60 cases. <i>Yonsei Medical Journal</i> , 1990, 31, 258.	0.9	14
53	A Study of Glomerular Minimal Lesion and Minimal Mesangial Proliferation with or without Nephrotic Syndrome; Pathologic, Immunopathologic and Clinical Correlations. <i>Yonsei Medical Journal</i> , 1986, 27, 17.	0.9	0
54	Examination of Use of Dreams in Psychoanalysis of a Young Man. <i>Yonsei Medical Journal</i> , 1982, 23, 167.	0.9	0

#	ARTICLE	IF	CITATIONS
55	Clinical Review of Miliary Tuberculosis in Korean Children -84 Cases and Review of the Literature-. Yonsei Medical Journal, 1969, 10, 146.	0.9	13